ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2405

Chat-GPT Performance in Diagnosis of Rheumatological Diseases: A Comparison with Specialist’s Opinion

Lucas Goncalves1 and Carlos Antonio Moura2, 1Bahiana School of Medicine and Public Health, Salvador, Bahia, Brazil, 2Bahiana School of Medicine and Public Health, Santo Antonio's Hospital, Sister Dulce's Social Works, Universidade Salvador (UNIFACS), Salvador, Bahia, Brazil

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, informatics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Despite Generative Pretrained Transformer Chat (Chat-GPT) is an artificial intelligence tool with the potential to assist doctors in diagnosing and treating patients, little is known about its assertiveness in the face of practical issues regarding autoimmune rheumatic diseases (ARDs). Therefore, we present a comparison between the answers provided by Chat-GPT 4.0 and rheumatologists of different degrees of experience to a specific questionnaire on Systemic lupus erythematosus (SLE), Rheumatoid arthritis (RA), Ankylosing spondylitis (AS),Psoriatic arthritis (PsA) and fibromyalgia (FM).
 
 

Methods: In this cross-sectional study we applied a questionnaire with five identical questions for each disease (SLE, RA, AS, PsA and FM, totaling 25 questions) to chat-GPT 4.0 and four pairs of rheumatologists with different levels of experience (less than 5 years of experience, 5 to 10, 11 to 20 and 21 to 30 years) being chosen 2 rheumatologists in each experience level. Two rheumatologists from academic services and with more than 30 years of experience blindly evaluated the responses in a binary way (agree or disagree). In case of discrepancy, a third rheumatologist from an academic service defined the evaluation.

 
 
 
 
 
 

Results: The best overall performance was observed in the group with 5 to 10 years of experience (70% of agreement probability with the evaluators) followed by chat-GPT 4.0 (68%). The worst overall performance was from the group with 21 to 30 years of experience (58%). Chat-GPT outperformed all other groups in questions concerning the first option for treatment and the most effective imaging exams for investigation (100% in both). IA was the one with the worst performance in questions about chose the most useful sign or symptom for diagnose each disease (40% compared to 90% attained by rheumatologists with 5 to 10 years of experience). Chat-GPT performed best compared to all groups on questions about SLE (80%, tied with the group with less than 5 years of experience) and FM (80%, tied with the groups with 5 to 10 and 11 to 20 years of experience).

 
 
 
 
 
 

Conclusion: Chat-GPT 4.0 had an excellent performance in issues that require less practical knowledge (choice of treatment and imaging exam for diagnosis). On the other hand, it performed significantly poorly on questions about choosing the most useful sign or symptom for diagnosis, which are answers that require an experience-based knowledge. However, chat-GPT 4.0 performed very satisfactorily, achieving higher scores than many experts who participated in the study. Such results, more than confirming the superiority or invalidity of the machine, point to the need to carry out more robust studies that explore the potential of using AI in rheumatology.

 
 
 
 
 
 

Supporting image 1

The five types were made with the five diseases totaling a questionnaire with twenty-five questions. AS: Ankylosing spondylitis; FM: Fibromyalgia; PsA: Psoriatic arthritis; RA: Rheumatoid arthritis; SLE; Systemic lupus erythematosus.
*All questions were submitted in Brazilian Portuguese.

Supporting image 2

y= years; Chat-GPT= Generative Pretrained Transformer Chat.

Supporting image 3

y= years; Chat-GPT= Generative Pretrained Transformer Chat.


Disclosures: L. Goncalves: None; C. Moura: None.

To cite this abstract in AMA style:

Goncalves L, Moura C. Chat-GPT Performance in Diagnosis of Rheumatological Diseases: A Comparison with Specialist’s Opinion [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/chat-gpt-performance-in-diagnosis-of-rheumatological-diseases-a-comparison-with-specialists-opinion/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/chat-gpt-performance-in-diagnosis-of-rheumatological-diseases-a-comparison-with-specialists-opinion/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology